COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

20/06/2024 - 14:30

AD04 reduced heavy drinking days among heavy drinking individuals with alcohol use disorder and a specific genetic profile, as identified by a companion diagnostic test (CDx) GLEN ALLEN, Va., June 20, 2024 (GLOBE [...]

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

20/06/2024 - 14:30

HOUSTON, TEXAS, June 20, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. [...]

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment

20/06/2024 - 14:30

Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration The results provide proof-of-concept for [...]

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

20/06/2024 - 14:30

Diabetes industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. ( [...]

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

20/06/2024 - 14:30

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY ™ Test [...]

Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe

20/06/2024 - 14:30

ATLANTA, June 20, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, [...]

Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector

20/06/2024 - 14:30

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]

Smart for Life to Attend the International Society of Sports Nutrition’s 2024 Conference

20/06/2024 - 14:30

Company to Engage with Industry Leaders and Identify Acquisition Opportunities in the Sports Nutrition Market MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “ [...]

Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

20/06/2024 - 14:25

Following FDA Approval to Commence the Clinical Trial, an Official Site Initiation Has Taken Place as Preparation for Patient Enrollment Advances Multiple Robotic Systems Already Received by the Site to Allow Inventory [...]

Cronos Group Announces Expansion of GrowCo to Fuel Global Growth

20/06/2024 - 14:12

TORONTO, June 20, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, announced an expansion of Cronos Growing Company (“GrowCo [...]

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

20/06/2024 - 14:00

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene [...]

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

20/06/2024 - 14:00

WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

20/06/2024 - 14:00

Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson’s disease CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., ( [...]

Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

20/06/2024 - 14:00

Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening and resistant bacteria SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- [...]

Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé

19/06/2024 - 21:31

Les données indiquent des tendances vers une réduction des toxicités et de meilleurs résultats pour les sujets recevant l’association ONIVYDE/5-FU et une thérapie ciblée par anti-IL-1alpha AUSTIN, Texas, 19 juin 2024 ( [...]

Healthcare Integrated Technologies, Inc. Welcomes Dustin Hillis as Chief Strategy Officer

19/06/2024 - 20:07

Knoxville, Tennessee, June 19, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leader in developing advanced healthcare technology solutions, is thrilled to announce the appointment of [...]

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

19/06/2024 - 18:15

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic C ompany’s Growth Nantes, France – June 19, 2024, 6:15pm CET – OSE [...]

OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société

19/06/2024 - 18:15

OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société Nantes, France – le 19 juin 2024, 18 heures [...]

New Report Tracks Revenue Generated by Allied Healthcare Professionals

19/06/2024 - 16:00

Revenues May Exceed $2 Million Per Year After Staffing Costs DALLAS, June 19, 2024 (GLOBE NEWSWIRE) -- Allied health professionals such as radiology technologists and therapists can generate millions of dollars a year [...]